Lonapegsomatropin

Therapeutic indications

Lonapegsomatropin is indicated for:

Growth hormone deficiency [GHD]

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [GHD]).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Lonapegsomatropin is contraindicated in the following cases:

Tumour

Neoplastic disease

Acute critical illness

at least one of
Cardiac insufficiency following cardiac surgery
Postoperative complication
Multiple injuries
Acute respiratory failure

Closed epiphyses

Population group: only children (1 year - 12 years old)

Premature epiphyseal closure

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL/PLR) 2021: SKYTROFA Powder for solution for injection
Summary of Product Characteristics (SPC) 2022: SKYTROFA Powder and solvent for solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈